Vaccine before surgery for HER2-positive breast duct cancer in place
Treatments studied
Part of Cancer clinical trials.
This Phase 1 study tests a vaccine (H2NVAC) given before surgery to help the body fight HER2-expressing ductal carcinoma in situ (DCIS) that has not been removed yet. Because it’s early-stage, the main goal is to check safety and learn how the treatment may work.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have DCIS that has not been surgically removed yet, and there should be no spread to lymph nodes or distant organs
- Your DCIS must show HER2 activity on biopsy (HER2 score can be low or high: +1, +2, or +3)
- You must be well enough for study visits (ECOG 0 to 2) and have no prior treatment for this DCIS
- You must be able to stop certain hormone-blocking medicines before vaccination (endocrine therapy during the vaccine/surgery period is not allowed)
- Your blood tests must be high enough (neutrophils, platelets, and hemoglobin) and your liver and kidney labs must be acceptable
- If you could become pregnant, you must use reliable birth control through 6 months after the last vaccine dose
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests whether adding a cancer vaccine (with GM-CSF) to standard HER2-targeted chemotherapy before surgery improves treatment outcomes for HER2-positive breast cancer. If you join, you’ll receive planned medicine before surgery to treat the tumor, then continue with the study schedule.
This trial tests a vaccine that targets a protein (MUC1) found in early breast cancer cells. It's for women with ER+ DCIS who are planning surgery, to see if the vaccine can help prevent the cancer from coming back or getting worse.
This Phase 2 study tests a personalized immune-therapy vaccine made from your immune cells, given with weekly paclitaxel and HER2-targeted antibodies (trastuzumab and pertuzumab). It aims to improve treatment outcomes for people with HER2-positive breast cancer before standard local treatment (like surgery and radiation).
This trial tests giving trastuzumab (a targeted drug) plus a chemotherapy drug called a taxane before surgery for women with HER2-positive ductal carcinoma in situ (DCIS), an early form of breast cancer. The goal is to see if this combination can shrink or eliminate the cancer before surgery.
This Phase 1 trial tests a new study drug called DC1 given before standard breast cancer treatments. It focuses on people with HER2-negative breast cancer that is “hormone negative” or “hormone low,” aiming to see if the treatment is safe and whether it may work before surgery or other local therapy.
This trial studies a faster, higher-frequency chemotherapy schedule given before surgery for HER2-negative breast cancer. It aims to see if this approach works better and is safe for the patient’s cancer stage.
Hear when a new Breast Ductal Carcinoma In Situ trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.